相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab
U. Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Adherence to Adalimumab Therapy in Crohn's Disease: A French Multicenter Experience
Vincent Billioud et al.
INFLAMMATORY BOWEL DISEASES (2011)
Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's Disease: Clinical Efficacy and Pharmacoeconomics
William J. Sandborn et al.
INFLAMMATORY BOWEL DISEASES (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Harry Sokol et al.
GUT (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England
E. A. Russo et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
A. Swaminath et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines
S. Ben-Horin et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
R. L. West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort
Lissy de Ridder et al.
INFLAMMATORY BOWEL DISEASES (2008)
Management of loss of response to anti-TNF drugs: Change the dose or change the drug?
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2008)
Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
G. G. Kaplan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
